Galapagos starts dosing in EQUATOR trial of filgotinib to treat psoriatic arthritis

Biotechnology firm Galapagos has started dosing patients in its Phase II EQUATOR clinical trial of filgotinib for the treatment of moderately to severely active psoriatic arthritis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news